Skip to main content
NaltrexoneReviews home

Explainer

Does Naltrexone Work?

What trials show about naltrexone's success rate for alcohol and opioids, why results vary, and what to check if it isn't working.

By Naltrexone Reviews Editorial TeamUpdated 29 sourcesHow we check

Short answer

Naltrexone works modestly for alcohol use disorder: in pooled trials, for every 11 people who took daily naltrexone tablets, 1 more avoided a return to heavy drinking than on placebo.1 For opioids, the monthly shot beat placebo; the daily pill did only when pill-taking was enforced.2,3

Key takeaways

  • It cuts heavy drinking more reliably than it stops drinking altogether. In a Cochrane review of 50 trials, the drop in return to any drinking missed statistical significance.4
  • Single trials ranged from no benefit, in a US Veterans Affairs (VA) trial of 627 veterans with chronic, severe dependence, to relapse rates cut by more than half. No one success rate exists.5,6
  • No test predicts who will respond.7,8 Guidelines set different checkpoints: England's NICE sets 4 to 6 weeks of continued drinking as the point to stop the tablets, and the US VA/DoD guideline judges them after 3 months at 50 mg a day.9,10

Naltrexone moves heavy drinking most

Pooled results are often given as a number needed to treat (NNT): how many people need the drug instead of a placebo for 1 more to benefit. A 2023 review of 118 trials of alcohol medicines, done for the Agency for Healthcare Research and Quality (AHRQ), found these NNTs for 50 mg naltrexone tablets1:

  • Return to heavy drinking: NNT 11 (95% confidence interval, 5 to 41).
  • Return to any drinking: NNT 18 (95% confidence interval, 4 to 32).

Both intervals are wide, so the real effect may be noticeably larger or smaller than the headline number.

The 2010 Cochrane review of 50 trials and 7,793 people found the risk of heavy drinking 17% lower and drinking days about 4% fewer. Its 4% lower risk of any drinking was not statistically significant.4 Comparisons with other alcohol medicines are in pooled results on the AUD page.

Success rates ranged from no benefit to relapse more than halved

Trials measured different outcomes in different people, so the naltrexone success rate depends on the trial. Five trials show the range:

Five trials of naltrexone against placebo for alcohol, from no benefit to relapse cut by more than half.

  • Trial: Volpicelli, 1992

    Who, and for how long
    70 men after alcohol detox; 50 mg tablets for 12 weeks
    Result vs placebo
    Relapse 23% vs 54.3%; less craving and fewer drinking days6
  • Trial: O'Malley, 1992

    Who, and for how long
    97 adults with alcohol dependence; tablets plus one of two talk therapies for 12 weeks
    Result vs placebo
    Better on abstinence, drinking days, relapse and alcohol problems11
  • Trial: VA trial (Krystal), 2001

    Who, and for how long
    627 veterans, almost all men, with chronic, severe dependence; 50 mg tablets for up to 12 months
    Result vs placebo
    No significant difference: 72.3 vs 62.4 days to relapse at 13 weeks, and no difference in drinking at 52 weeks5
  • Trial: Garbutt, 2005 (Vivitrol shot)

    Who, and for how long
    627 alcohol-dependent adults, most still drinking at the first shot; monthly shots for 6 months
    Result vs placebo
    Heavy drinking days 25% less frequent on the 380 mg dose12
  • Trial: COMBINE, 2006

    Who, and for how long
    1,383 recently abstinent adults; 100 mg tablets a day plus brief medical check-ins for 16 weeks
    Result vs placebo
    Alcohol-free days 80.6% vs 75.1%; risk of a heavy drinking day 28% lower over time13

The Sinclair Method's 78% figure comes from an uncontrolled clinic program, not a trial: see where the 78% comes from.14

Pill-taking explains part of the gap between trials

In a 97-person trial, naltrexone's effect across everyone was modest. It was larger, on several outcomes, in people who finished treatment and took their pills.15 A compliance analysis of a 160-person trial found the benefit of naltrexone combined with cognitive behavioral therapy roughly doubled in size (an effect size of about 0.2, rising to about 0.4 to 0.5) when limited to people who took their medicine.16 These subgroups were not randomized, and in the second trial, age predicted who took the pills.16

The VA trial offered every participant a program to improve pill-taking and still found no difference.5 A 2007 reanalysis of that trial and a second negative trial, in women, sorted people by their day-to-day drinking pattern. Naltrexone doubled the odds of following an "abstainer" pattern rather than a "consistent drinker" one, with no significant effect on abstainer versus occasional-drinker patterns.17 It reanalyzed the same two trials and added no new participants.

Nor can anyone yet pick likely responders in advance: family history and a gene variant have been studied without a clear answer (no test predicts who it will help).7,8

When it works, craving and the pace of drinking drop

Naltrexone blocks opioid receptors in the brain involved in the reward from drinking.18 It is not aversive: drinking on it does not cause a disulfiram-like sickness reaction.19

In a laboratory study, 18 people with alcohol dependence who were not seeking treatment took naltrexone or placebo for 6 days, then had a starter drink and the chance to order up to 8 more. Both groups responded alike to the first drink. After it, people on naltrexone drank fewer drinks, more slowly, and reported less craving.20

In the 1992 Volpicelli trial, the difference showed up after a slip. Of the people who drank at all during treatment, 19 of 20 on placebo went on to relapse, against 8 of 16 on naltrexone.6 How soon these effects begin is covered in how long does naltrexone take to work?

You can start the tablets while still drinking

Naltrexone tablets can be started while someone is still drinking.18 The APA recommendation covers people aiming to cut down as well as people aiming to stop.21

The shot is different. In its main trial, heavy drinking days fell overall. Its extra gains on drinking days and abstinence were confined to the small group (8%) who had gone a week without alcohol before the first shot. For the other 92%, the label says those effects "were not evident."22 What a drink feels like on naltrexone is covered in drinking on naltrexone.

Naltrexone not working? Five things to check

  1. Are you taking it every day? Trial participants who took their pills did better (see above).15
  2. Has it been long enough? NICE, writing for people who start after assisted withdrawal, says to stop if drinking persists 4 to 6 weeks in; the VA/DoD guideline gives 3 months at 50 mg a day.9,10 Early timing is on how long does naltrexone take to work?
  3. Is there support around it? The tablet label says it has not been shown to help except as part of a wider treatment program.19 The support can be light: in COMBINE, adding an intensive behavioral therapy did not beat naltrexone with brief medical check-ins.13
  4. What dose are you on? The label dose is 50 mg a day; COMBINE used 100 mg, twice the label dose.13,19 A SAMHSA advisory lists raising the dose among general options after a relapse on any alcohol medicine, without naming a naltrexone dose. The tablet label notes a possibly higher risk of liver injury with single doses above 50 mg.19,23 Don't change the dose on your own.
  5. Would another medicine fit better? If one alcohol medicine doesn't help, trying another is often worthwhile.18 The VA/DoD guideline rates topiramate (off-label in the US) in the same top tier as naltrexone, with acamprosate and disulfiram one tier lower.10 See how naltrexone compares with other medicines to stop drinking, or compare naltrexone vs acamprosate, the monthly Vivitrol shot and naltrexone vs disulfiram.

For opioids, the shot has stronger evidence than the daily pill

A 2011 Cochrane review of 13 trials with 1,158 people found oral naltrexone no better than placebo or no medicine on its main outcomes, and only 28% of participants stayed in treatment. In trials where taking the pill was enforced, it did better on retention and abstinence (risk ratio 2.93).2

The monthly shot has stronger trials. In a 24-week trial of 250 adults in Russia after detox, people on Vivitrol had confirmed opioid-free results in a median 90% of weeks, against 35% on placebo.3 In the X:BOT trial of 570 US adults, fewer people managed to start Vivitrol than Suboxone (72% vs 94%), and among those who did start, relapse rates were similar.24 For opioid use disorder, the VA/DoD guideline recommends buprenorphine or methadone and only suggests the shot.10 Starting rules and overdose records for the shot and Suboxone are compared on naltrexone vs Suboxone.

Once naltrexone wears off, an opioid dose a person used to tolerate can kill: see the overdose warning.19 Naltrexone is a different drug from naloxone (Narcan); see naltrexone vs naloxone.

Only 2.5% of people with alcohol use disorder get medication

In 2024, 2.5% of people in the US aged 12 and older with alcohol use disorder (about 697,000 of an estimated 28.0 million) received medication for it.25,26 Both US guidelines put naltrexone in their top tier: grade 1B from the APA and "Strong for" from the VA/DoD.10,21

Prescribing it needs no special training or license, according to NIAAA, which also calls the approved alcohol medicines non-addictive and says misinformation makes some patients hesitate.18 FDA removed the boxed liver warning from the ReVia tablet label in October 2013; the current tablet label still warns about liver injury.19,27

Weight loss and low-dose naltrexone are separate questions

Naltrexone tablets are approved for alcohol dependence and for blocking the effects of opioids, not for weight loss.19 Contrave, which combines naltrexone with bupropion, is approved alongside diet and exercise for weight management in some adults with obesity or overweight.28 Low-dose naltrexone (LDN) is an off-label use with separate evidence, covered on low-dose naltrexone.

Share your experience

Did naltrexone help you, or not? Tell us how it went, including if it didn't work, or read other people's naltrexone reviews.

Frequently asked questions

Is naltrexone worth taking?

For alcohol use disorder, both US guidelines rate it top tier, and pooled trials show a modest benefit, mostly on heavy drinking. See if it isn't working.1,10,21

What is the success rate of naltrexone?

There is no single figure. In pooled trials, 1 more person in every 11 avoided a return to heavy drinking compared with placebo. See the trials.1

Does naltrexone reduce cravings?

In some studies. Craving was lower on naltrexone in the 1992 Volpicelli trial and in a 6-day laboratory study. See what it feels like.6,20

Does naltrexone work if you keep drinking?

The tablets can be started while drinking, and the APA recommendation covers cutting down. The shot's label reports its added drinking benefits in people who had stopped drinking before the first dose. See starting while drinking.18,21,22

Why don't doctors prescribe naltrexone more?

NIAAA notes that some patients hesitate because of misinformation, and that prescribers need no special training. See who gets medication.18

Does naltrexone work for opioid addiction?

The monthly shot beat placebo in a 250-person trial. The daily pill was no better than placebo in a Cochrane review, except where pill-taking was enforced. See opioids and naltrexone vs Suboxone.2,3

How we checked

  • Sources include trial abstracts, the 2023 AHRQ review, Cochrane reviews (2010, 2011), current labels, the APA, VA/DoD and NICE guidelines, and NIAAA's 2024 treatment figures.1,2,4,9,10,19,21,22,26
  • The trial table counts 5 trials; two reanalyses are not counted again.
  • Relapse figures, AHRQ NNTs with their 95% confidence intervals, Cochrane risk figures and the Garbutt and COMBINE outcomes were checked against saved copies on October 17, 2026.

Programs that prescribe naltrexone

Online programs that prescribe naltrexone for alcohol, with their posted prices, are compared on where to get naltrexone online.

References

29 sources, numbered in the order they are first cited (AMA style). Each is labelled by type so you can weigh it; commercial and media sources are never the only support for a clinical claim.

  1. 1.McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA. 2023;330(17):1653-1665. doi:10.1001/jama.2023.19761Systematic review / meta-analysis · Our summary of this study
  2. 2.Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333. doi:10.1002/14651858.CD001333.pub4Systematic review / meta-analysis · Our summary of this study
  3. 3.Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513. doi:10.1016/S0140-6736(11)60358-9Randomized controlled trial · Our summary of this study
  4. 4.Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867. doi:10.1002/14651858.CD001867.pub3Systematic review / meta-analysis · Our summary of this study
  5. 5.Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739. doi:10.1056/NEJMoa011127Randomized controlled trial · Our summary of this study
  6. 6.Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876-880. doi:10.1001/archpsyc.1992.01820110040006Randomized controlled trial · Our summary of this study
  7. 7.Garbutt JC, Greenblatt AM, West SL, et al. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014;109(8):1274-1284. doi:10.1111/add.12557Systematic review / meta-analysis · Our summary of this study
  8. 8.Hartwell EE, Feinn R, Morris PE, et al. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020;115(8):1426-1437. doi:10.1111/add.14975Systematic review / meta-analysis · Our summary of this study
  9. 9.National Institute for Health and Care Excellence. Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking (High-Risk Drinking) and Alcohol Dependence. Clinical guideline CG115. Published February 23, 2011. Updated October 21, 2014. Accessed October 17, 2026. https://www.nice.org.uk/guidance/cg115/chapter/RecommendationsClinical guideline
  10. 10.US Department of Veterans Affairs; US Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 5.0. 2021. Accessed October 17, 2026. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/sud/VA-DoD-SUD-CPG_Final_for-508_v3.pdfClinical guideline
  11. 11.O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49(11):881-887. doi:10.1001/archpsyc.1992.01820110045007Randomized controlled trial · Our summary of this study
  12. 12.Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-1625. doi:10.1001/jama.293.13.1617Randomized controlled trial · Our summary of this study
  13. 13.Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017. doi:10.1001/jama.295.17.2003Randomized controlled trial · Our summary of this study
  14. 14.Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001;36(1):2-10. doi:10.1093/alcalc/36.1.2Narrative review · Narrative review written by the method's developer.
  15. 15.Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737-742. doi:10.1001/archpsyc.1997.01830200071010Randomized controlled trial · Our summary of this study
  16. 16.Baros AM, Latham PK, Moak DH, Voronin K, Anton RF. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007;31(4):596-603. doi:10.1111/j.1530-0277.2007.00343.xResearch study · Our summary of this study
  17. 17.Gueorguieva R, Wu R, Pittman B, et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry. 2007;61(11):1290-1295. doi:10.1016/j.biopsych.2006.09.038Research study · Our summary of this study
  18. 18.Recommend evidence-based treatment: know the options. In: Core Resource on Alcohol. National Institute on Alcohol Abuse and Alcoholism. Revised May 8, 2025. Accessed October 17, 2026. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/recommend-evidence-based-treatment-know-optionsGovernment source
  19. 19.Naltrexone hydrochloride tablets USP, 50 mg. Prescribing information. SpecGx LLC; revised May 2026. DailyMed SPL version 15. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06ff2d5a-e62b-4fa4-bbdb-01938535bc65FDA drug label
  20. 20.O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl). 2002;160(1):19-29. doi:10.1007/s002130100919Randomized controlled trial · Our summary of this study
  21. 21.American Psychiatric Association. Guideline statement summary. In: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. American Psychiatric Association Publishing; 2018. Accessed October 17, 2026. doi:10.1176/appi.books.9781615371969Clinical guideline
  22. 22.Vivitrol (naltrexone for extended-release injectable suspension). Prescribing information. Alkermes, Inc.; revised May 2026. DailyMed SPL version 39. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703fFDA drug label
  23. 23.Substance Abuse and Mental Health Services Administration. Prescribing Pharmacotherapies for Patients With Alcohol Use Disorder. Advisory. Publication No. PEP20-02-02-015. SAMHSA; 2021. Accessed October 17, 2026. https://library.samhsa.gov/sites/default/files/PEP20-02-02-015.pdfClinical guideline
  24. 24.Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318. doi:10.1016/S0140-6736(17)32812-XRandomized controlled trial · Our summary of this study
  25. 25.Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Table 5.21B: received medications for alcohol use disorder (MAUD) in past year: among people aged 12 or older; received MAUD in past year: among people aged 12 or older with past year alcohol use disorder; by demographic characteristics, percentages, 2023 and 2024. In: Results From the 2024 National Survey on Drug Use and Health: Detailed Tables. SAMHSA; 2025. Accessed October 17, 2026. https://www.samhsa.gov/data/sites/default/files/reports/rpt56484/NSDUHDetailedTabs2024/NSDUHDetailedTabs2024/2024-nsduh-detailed-tables-sect5pe.htmGovernment source
  26. 26.Alcohol treatment in the United States: age groups and demographic characteristics. National Institute on Alcohol Abuse and Alcoholism. Updated March 2026. Accessed October 17, 2026. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-treatment-united-states-age-groups-and-demographic-characteristicsGovernment source
  27. 27.US Food and Drug Administration. Revia (naltrexone HCl) tablets: detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). MedWatch Safety Information. October 2013. Internet Archive capture November 9, 2015. Accessed October 17, 2026. https://web.archive.org/web/20151109023859/http://www.fda.gov/safety/medwatch/safetyinformation/ucm374896.htmGovernment source · Archived copy (Internet Archive).
  28. 28.Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets. Prescribing information. Nalpropion Pharmaceuticals LLC; revised November 2025. DailyMed SPL version 27. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51bFDA drug label
  29. 29.SAMHSA's National Helpline. Substance Abuse and Mental Health Services Administration. Updated June 9, 2023. Accessed October 17, 2026. https://www.samhsa.gov/find-help/helplines/national-helplineGovernment source

Medical disclaimer

This page is for general information only and is not medical advice. It does not replace advice from your own clinician or pharmacist. Don't start, stop or change a medicine without talking to your prescriber. If you drink heavily every day, stopping suddenly can be dangerous; get medical advice first. If you use opioids, starting naltrexone in either form can cause sudden, severe withdrawal. For free, confidential treatment referrals 24 hours a day, call SAMHSA's National Helpline at 1-800-662-4357.29

Full medical disclaimer.